Why Supernus (SUPN) is Poised to Beat Earnings Estimates Again

Core Viewpoint - Supernus Pharmaceuticals (SUPN) has consistently exceeded earnings estimates and is well-positioned for future earnings growth, particularly with its upcoming quarterly report expected on November 4, 2025 [1][8]. Earnings Performance - In the last reported quarter, Supernus achieved earnings of $0.91 per share, significantly surpassing the Zacks Consensus Estimate of $0.47 per share, resulting in a surprise of 93.62% [2]. - For the previous quarter, the company reported earnings of $0.42 per share against an expectation of $0.38 per share, delivering a surprise of 10.53% [2]. Earnings Estimates and Predictions - Recent estimates for Supernus have been increasing, with a positive Earnings ESP (Expected Surprise Prediction) of +11.86%, indicating growing analyst optimism regarding its near-term earnings potential [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank 1 (Strong Buy) suggests a high likelihood of another earnings beat in the upcoming report [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7].